Whalesbook
Toh bhaiyo, suno India ki pharma industry ka naya update. Feb FY26 tak, apna pharma export $28.29 billion tak pahunch gaya hai. Yeh pichle saal ke comparison mein 5.6% zyada hai. Last year toh humne $30.47 billion ka export kiya tha, matlab growth toh dikha raha hai, par pehle jitni speed se nahi. Pichle saal 9.4% ka jump mila tha. Abhi apni pharma industry $60 billion ke aas paas hai aur 2030 tak toh $130 billion cross karne ka target hai.
Lekin baat sirf numbers ki nahi hai, asal challenges ab samne aa rahe hain. Nifty Pharma Index March 2026 tak lagbhag flat hi raha hai, jabki Nifty 50 10% se bhi zyada gira tha. Iska matlab pharma abhi stable hai, par growth mein thoda pressure hai. US market mein sales thoda slow chal raha hai, aur global pharma production bhi 2025 mein toofani hone ke baad ab sirf 1.6% grow karega 2026 mein.
Ab companies sirf generic drugs banane se hat kar innovation pe dhyan de rahi hain. Complex generics, biosimilars, speciality products pe focus badh raha hai. USFDA ki inspections ab improved hain, 'Official Action Indicated' (OAI) cases 8% ho gaye hain 2025 mein, jo 2015 mein 12% the. Lekin, Sun Pharma ke Halol plant ko June 2025 mein OAI mila tha, matlab abhi bhi risks hain. US ke naye trade rules bhi uncertainty la rahe hain, jaise patented drugs par naya tariff. Abhi generics ko chhoot hai, par future mein kya hoga, keh nahi sakte.
Aur toh aur, West Asia mein chal rahe conflicts ne shipping routes ko disrupt kar diya hai. Freight costs badh gaye hain, delays ho rahe hain, specially temperature-controlled shipments ke liye. Sirf March mein hi is wajah se exporters ko ₹2,500 se ₹5,000 crore tak ka nuksan ho sakta hai Gulf regions mein jaane wale shipments par. R&D mein bhi humara investment global players se kam hai, sirf 7-8% revenue ka, jo future innovation ke liye achha nahi hai.
So, export numbers toh badh rahe hain, par andar ki baat ye hai ki future mein aur zyada tough competition aur regulations face karne padenge. USFDA aur EU ke strict rules, US market mein pricing ka pressure, aur supply chain ki problems – yeh sab risk badha rahe hain. Chhote companies ke liye toh yeh aur bhi mushkil hai. Sabse bade players jaise Sun Pharma (P/E ~37), Dr. Reddy's Laboratories (P/E ~18), Cipla (P/E ~21), aur Lupin (P/E ~22.5)** ka P/E ratio dikhata hai ki investors in challenges ko kaise dekh rahe hain. Dr. Reddy's Laboratories toh ek balanced strategy mein lagta hai, jabki Sun Pharma ka valuation uske size aur speciality products pe confidence dikhata hai.
Abhi analysts keh rahe hain ki FY2026 mein India pharma sector 9-11% grow kar sakta hai, domestic demand aur Europe jaise markets ki wajah se. Companies ko quality, sustainability pe dhyan dena hoga aur alag alag markets mein diversify karna hoga. Innovation aur high-value products pe focus future ke liye achha hai. Lekin asal success is baat par depend karegi ki industry regulations, supply chain issues aur R&D mein kitna adapt kar pati hai.